**Supplementary Table 3**. Comparison of baseline characteristics of the patients with known week one metabolite data compared with those without week one metabolite data available.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Week one levels available (n=267) | No week one levels available (n=500) | p-value |
| Gender, male, n (%) | 116 (43) | 230 (46) | 0.49 |
| Age (years), median (IQR) | 39.9 (26.0-52.4) | 41.2 (26.8-53.4) | 0.75 |
| Weight, mean kg (SD) | 73.9 (16.2) | 74.6 (16.1) | 0.61 |
| Drug, AZA, n (%) | 182 (68) | 312 (62) | 0.11 |
| Randomized for genotyping, n (%) | 134 (50) | 264 (53) | 0.49 |
| Heterozygous *TPMT* genotype, n (%) | 24 (9.0) | 48 (9.6) | 0.78 |
| TPMT activity in mg/mmol Hb.h, mean (SD) | 89.9 (21.9) | 90.6 (22.7) | 0.69 |
| Disease, CD, n (%) | 147 (55) | 316 (63) | 0.09 |
| Dosage in mg/kg, median (IQR) a | 1.07 (1.00-1.17) | 1.10 (1.01-1.19) | 0.18 |

a AZA doses was divided by 2.08 and pooled with MP dosage to compare dosage in mg/kg. AZA, azathioprine; CD, Crohn’s disease; MP, mercaptopurine ; TPMT, thiopurine S-methyltransferase